Cardiology overview heart failure: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 7: | Line 7: | ||
*Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway. | *Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway. | ||
===Metformin=== | |||
*[[Metformin]] use in [[diabetics]] with [[CHF]] is associated with lower mortality | |||
==Obstructive Sleep Apnea in the Patient with CHF== | ==Obstructive Sleep Apnea in the Patient with CHF== | ||
Revision as of 15:18, 31 October 2011
|
Cardiology Overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Pharmacotherapy
Lasix
- Higher lasix doses are associated with higher mortality, likely as a surrogate of disease severity rather than part of a causal pathway.
Metformin
Obstructive Sleep Apnea in the Patient with CHF
- Central sleep apnea in the patient with CHF is due to the compensatory respiratory alkalosis that is present in the patient with CHF and tachypnea